Alley Investment Management Company LLC Has $641,000 Position in Johnson & Johnson (NYSE:JNJ)

Alley Investment Management Company LLC reduced its stake in shares of Johnson & Johnson (NYSE:JNJ) by 1.5% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 4,429 shares of the company’s stock after selling 66 shares during the quarter. Alley Investment Management Company LLC’s holdings in Johnson & Johnson were worth $641,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the stock. Ring Mountain Capital LLC bought a new position in shares of Johnson & Johnson during the 4th quarter valued at about $318,000. Exencial Wealth Advisors LLC lifted its holdings in shares of Johnson & Johnson by 2.3% during the 4th quarter. Exencial Wealth Advisors LLC now owns 44,573 shares of the company’s stock valued at $6,446,000 after purchasing an additional 1,000 shares in the last quarter. AMJ Financial Wealth Management lifted its holdings in shares of Johnson & Johnson by 508.2% during the 4th quarter. AMJ Financial Wealth Management now owns 6,806 shares of the company’s stock valued at $160,000 after purchasing an additional 5,687 shares in the last quarter. Commerzbank Aktiengesellschaft FI lifted its holdings in shares of Johnson & Johnson by 7.8% during the 4th quarter. Commerzbank Aktiengesellschaft FI now owns 1,076,053 shares of the company’s stock valued at $155,619,000 after purchasing an additional 78,141 shares in the last quarter. Finally, Synergy Investment Management LLC bought a new stake in Johnson & Johnson in the 4th quarter valued at approximately $380,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ opened at $165.22 on Thursday. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The stock’s fifty day moving average price is $152.11 and its two-hundred day moving average price is $156.19. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99. The firm has a market cap of $397.79 billion, a price-to-earnings ratio of 24.85, a P/E/G ratio of 2.56 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The firm had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. During the same period in the prior year, the firm posted $2.29 EPS. The company’s revenue for the quarter was up 5.3% on a year-over-year basis. On average, equities analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th were issued a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 3.00%. The ex-dividend date of this dividend was Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 74.59%.

Insider Transactions at Johnson & Johnson

In related news, Director Mark A. Weinberger bought 1,000 shares of Johnson & Johnson stock in a transaction dated Thursday, December 12th. The shares were bought at an average cost of $147.22 per share, with a total value of $147,220.00. Following the acquisition, the director now owns 1,000 shares in the company, valued at $147,220. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, VP Robert J. Decker sold 6,999 shares of the stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the sale, the vice president now directly owns 21,001 shares in the company, valued at approximately $3,483,645.88. This trade represents a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

JNJ has been the topic of several research reports. Citigroup cut their target price on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a research note on Wednesday, December 11th. Leerink Partners cut their target price on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. Bank of America boosted their target price on Johnson & Johnson from $159.00 to $171.00 and gave the company a “neutral” rating in a research note on Wednesday. Raymond James cut their target price on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. Finally, Barclays upped their price objective on Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a research note on Tuesday, January 28th. Nine investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $171.33.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.